Mapping of molecular pathways, biomarkers and drug targets for diabetic nephropathy

Proteomics - Clinical Applications

Volumn 5, Issue 5-6, 2011, Pages 354-366

  Fechete, Raul ^a   Heinzel, Andreas ^a   Perco, Paul ^a   Mönks, Konrad ^b   Söllner, Johannes ^a   Stelzer, Gil ^c   Eder, Susanne ^b   Lancet, Doron ^c   Oberbauer, Rainer ^d   Mayer, Gert ^b   Mayer, Bernd ^a,e  

^a Emergentec Biodevelopment GmbH   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY OF VIENNA   (Austria)

Author keywords

Biomarker; Data integration; Modeling; Network; Target

Indexed keywords

AMINOPEPTIDASE P; ANGIOTENSIN CONVERTING ENZYME 2; ATENOLOL; ATORVASTATIN; BIOLOGICAL MARKER; BOSENTAN; CANDESARTAN; CHOLECYSTOKININ; CHYMASE; CLONIDINE; CORTICOTROPIN; DIPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE; DOXAZOSIN; EXENDIN 4; FOLIC ACID; GLUTAMYL AMINOPEPTIDASE; IRBESARTAN; LOSARTAN; PERINDOPRIL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROTEOME; RENIN; SERTRALINE; SIMVASTATIN; SPIRONOLACTONE; STRATUM CORNEUM CHYMOTRYPTIC ENZYME; TELMISARTAN; UNINDEXED DRUG; VALSARTAN;

ARTICLE; DATA MINING; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG TARGETING; HUMAN; HYPERTENSION; METABOLOMICS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEOMICS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTOMICS;

EID: 79957614666     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201000136     Document Type: Article

References (69)

1. Newman, D. J., Mattock, M. B., Dawnay, A. B., Kerry, S. et al., Systematic review on urine albumin testing for early detection of diabetic complications. Health Technol. Assess 2005, 9, iii-vi, xiii-163.
2. Bojestig, M., Arnqvist, H. J., Hermansson, G., Karlberg, B. E., Ludvigsson, J., Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1994, 330, 15-18.
3. Finne, P., Reunanen, A., Stenman, S., Groop, P. H., Gronhagen-Riska, C., Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA 2005, 294, 1782-1787.
4. Adler, A. I., Stevens, R. J., Manley, S. E., Bilous, R. W. et al., Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003, 63, 225-232.
5. Wild, S., Roglic, G., Green, A., Sicree, R., King, H., Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27, 1047-1053.
6. Ozyilmaz, A., Bakker, S. J., de Zeeuw, D., de Jong, P. E., Gansevoort, R. T., Selection on albuminuria enhances the efficacy of screening for cardiovascular risk factors. Nephrol. Dial. Transplant. 2010, 25, 3560-3568.
7. Mann, J. F., Schmieder, R. E., McQueen, M., Dyal, L. et al., Renal outcomes with telmisartan ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet. 2008, 372, 547-553.
8. Bakris, G. L., Sarafidis, P. A., Weir, M. R., Dahlof, B. et al., Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010, 375, 1173-1181.
9. Levey, A. S., Cattran, D., Friedman, A., Miller, W. G. et al., Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am. J. Kidney Dis. 2009, 54, 205-226.
10. Blezquez-Medela, A. M., Lopez-Novoa, J. M., Martinez-Salgado, C., Mechanisms involved in the genesis of diabetic nephropathy. Curr. Diabetes Rev. 2010, 6, 68-87.
11. Cushman, W. C., Evans, G. W., Byington, R. P., Goff, D. C., Jr., et al., Effects of intensive blood-pressure control in type 2 diabetes mellitus. N. Engl. J. Med. 2010, 362, 1575-1585.
12. Fioretto, P., Steffes, M. W., Sutherland, D. E., Goetz, F. C., Mauer, M., Reversal of lesions of diabetic nephropathy after pancreas transplantation. N. Engl. J. Med. 1998, 339, 69-75.
13. Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., Neil, H. A., 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 2008, 359, 1577-1589.
14. Holman, R. R., Paul, S. K., Bethel, M. A., Neil, H. A., Matthews, D. R., Long-term follow-up after tight control of blood pressure in type 2 diabetes. N. Engl. J. Med. 2008, 359, 1565-1576.
15. KDOQI Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am. J. Kidney Dis. 2007, 49 (suppl. 2), s12-s154.
16. Pan, Y., Guo, L. L., Jin, H. M., Low-protein diet for diabetic nephropathy: a meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 2008, 88, 660-666.
17. Gaede, P., Vedel, P., Larsen, N., Jensen, G. V. et al., Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 2003, 348, 383-393.
18. Howard, B. V., Roman, M. J., Devereux, R. B., Fleg, J. L. et al., Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA 2008, 299, 1678-1689.
19. Köttgen, A., Pattaro, C., Böger, C. A., Fuchsberger, C. et al., New loci associated with kidney function and chronic kidney disease. Nat. Genet. 2010, 42, 376-384.
20. Cohen, C. D., Lindenmeyer, M. T., Eichinger, F., Hahn, A. et al., Improved elucidation of biological processes linked to diabetic nephropathy by single probe-based microarray data analysis. PLoS One 2008, 3, e2937.
21. Merchant, M. L., Klein, J. B., Proteomics and diabetic nephropathy. Curr. Diab. Rep. 2005, 5, 464-469.
22. Sebedio, J. L., Pujos-Guillot, E., Ferrara, M., Metabolomics in evaluation of glucose disorders. Curr. Opin. Clin. Nutr. Metab. Care 2009, 12, 412-418.
23. Rossing, K., Mischak, H., Dakna, M., Zurbig, P. et al., Urinary proteomics in diabetes and CKD. J. Am. Soc. Nephrol. 2008, 19, 1283-1290.
24. Alkhalaf, A., Zurbig, P., Bakker, S. J., Bilo, H. J. et al., Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. PLoS One 2010, 5, e13421.
25. Fox, C. S., Gona, P., Larson, M. G., Selhub, J. et al., A multi-marker approach to predict incident CKD and microalbuminuria. J. Am. Soc. Nephrol. 2010, 21, 2143-2149.
26. Molina, F., Dehmer, M., Perco, P., Graber, A. et al., Systems biology: opening new avenues in clinical research. Nephrol. Dial. Transplant. 2010, 25, 735-743.
27. Mühlberger, I., Mönks, K., Bernthaler, A., Jandrasits, C. et al., Integrative bioinformatics analysis of proteins associated with the cardiorenal syndrome. Int. J. Nephrol. 2011, 2011, 10.
28. Perco, P., Wilflingseder, J., Bernthaler, A., Wiesinger, M. et al., Biomarker candidates for cardiovascular disease and bone metabolism disorders in chronic kidney disease: a systems biology perspective. J. Cell. Mol. Med. 2008, 12, 1177-1187.
29. Lusis, A. J., Weiss, J. N., Cardiovascular networks: systems-based approaches to cardiovascular disease. Circulation 2010, 121, 157-170.
30. Hidalgo, C. A., Blumm, N., Barabasi, A. L., Christakis, N. A., A dynamic network approach for the study of human phenotypes. PLoS Comput. Biol. 2009, 5, e1000353.
31. Barrenas, F., Chavali, S., Holme, P., Mobini, R., Benson, M., Network properties of complex human disease genes identified through genome-wide association studies. PLoS One 2009, 4, e8090.
32. Dezso, Z., Nikolsky, Y., Nikolskaya, T., Miller, J. et al., Identifying disease-specific genes based on their topological significance in protein networks. BMC Syst. Biol. 2009, 3, 36.
33. Dudley, J. T., Butte, A. J., Identification of discriminating biomarkers for human disease using integrative network biology. Pac. Symp. Biocomput. 2009, 27-38.
34. Goh, K. I., Cusick, M. E., Valle, D., Childs, B. et al., The human disease network. Proc. Natl. Acad. Sci. USA 2007, 104, 8685-8690.
35. Ozgur, A., Vu, T., Erkan, G., Radev, D. R., Identifying gene-disease associations using centrality on a literature mined gene-interaction network. Bioinformatics 2008, 24, i277-285.
36. Xu, M., Kao, M. C., Nunez-Iglesias, J., Nevins, J. R. et al., An integrative approach to characterize disease-specific pathways and their coordination: a case study in cancer. BMC Genomics 2008, 9, S12.
37. Li, J., Zhu, X., Chen, J. Y., Building disease-specific drug-protein connectivity maps from molecular interaction networks and PubMed abstracts. PLoS Comput. Biol. 2009, 5, e1000450.
38. Wishart, D. S., Knox, C., Guo, A. C., Eisner, R. et al., HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res. 2009, 37, D603-D610.
39. Wishart, D. S., Knox, C., Guo, A. C., Cheng, D. et al., DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008, 36, D901-D906.
40. Bernthaler, A., Mühlberger, I., Fechete, R., Perco, P. et al., A dependency graph approach for the analysis of differential gene expression profiles. Mol. Biosyst. 2009, 5, 1720-1731.
41. Johnson, B., Shneiderman, B., Proceedings of the 2nd Conference on Visualization '91, IEEE Computer Society Press, San Diego, California 1991.
42. Rapberger, R., Perco, P., Sax, C., Pangerl, T. et al., Linking the ovarian cancer transcriptome and immunome. BMC Syst. Biol. 2008, 2, 2.
43. Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S. et al., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102, 15545-15550.
44. Sengupta, U., Ukil, S., Dimitrova, N., Agrawal, S., Expression-based network biology identifies alteration in key regulatory pathways of type 2 diabetes and associated risk/complications. PLoS One 2009, 4, e8100.
45. Mironidou-Tzouveleki, M., Tsartsalis, S., Tomos, C., Vascular endothelial growth factor (VEGF) in the pathogenesis of diabetic nephropathy of type 1 diabetes mellitus. Curr. Drug Targets 2011, 12, 107-114.
46. Rudnicki, M., Perco, P., Enrich, J., Eder, S. et al., Hypoxia response and VEGF-A expression in human proximal tubular epithelial cells in stable and progressive renal disease. Lab. Invest. 2009, 89, 337-346.
47. Jiang, W., Zhang, Y., Wu, H., Zhang, X. et al., Role of cross-talk between the Smad2 and MAPK pathways in TGF-beta1-induced collagen IV expression in mesangial cells. Int. J. Mol. Med. 2010, 26, 571-576.
48. Parkinson, H., Kapushesky, M., Kolesnikov, N., Rustici, G. et al., ArrayExpress update--from an archive of functional genomics experiments to the atlas of gene expression. Nucleic Acids Res. 2009, 37, D868-D872.
49. Vizcaino, J. A., Cote, R., Reisinger, F., Foster, J. M. et al., A guide to the Proteomics Identifications Database proteomics data repository. Proteomics 2009, 9, 4276-4283.
50. Safran, M., Dalah, I., Alexander, J., Rosen, N. et al., GeneCards Version 3: the human gene integrator. Database (Oxford) 2010, baq020.
51. Morita, Y., Ikeguchi, H., Nakamura, J., Hotta, N. et al., Complement activation products in the urine from proteinuric patients. J. Am. Soc. Nephrol. 2000, 11, 700-707.
52. Markiewski, M. M., Nilsson, B., Ekdahl, K. N., Mollnes, T. E., Lambris, J. D., Complement and coagulation: strangers or partners in crime? Trends Immunol. 2007, 28, 184-192.
53. Lambers Heerspink, H. J., Fowler, M. J., Volgi, J., Reutens, A. T. et al., Rationale for and study design of the sulodexide trials in Type 2 diabetic, hypertensive patients with microalbuminuria or overt nephropathy. Diabet. Med. 2007, 24, 1290-1295.
54. Kume, S., Uzu, T., Isshiki, K., Koya, D., Peroxisome proliferator-activated receptors in diabetic nephropathy. PPAR Res. 2008, 2008, 879523.
55. Baelde, H. J., Eikmans, M., Doran, P. P., Lappin, D. W. et al., Gene expression profiling in glomeruli from human kidneys with diabetic nephropathy. Am. J. Kidney Dis. 2004, 43, 636-650.
56. Berthier, C. C., Zhang, H., Schin, M., Henger, A. et al., Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes 2009, 58, 469-477.
57. Cohen, C. D., Lindenmeyer, M. T., Eichinger, F., Hahn, A. et al., Improved elucidation of biological processes linked to diabetic nephropathy by single probe-based microarray data analysis. PLoS One 2008, 3, e2937.
58. Rudnicki, M., Eder, S., Perco, P., Enrich, J. et al., Gene expression profiles of human proximal tubular epithelial cells in proteinuric nephropathies. Kidney Int. 2007, 71, 325-335.
59. Dihazi, H., Müller, G. A., Lindner, S., Meyer, M. et al., Characterization of diabetic nephropathy by urinary proteomic analysis: identification of a processed ubiqutin form as a differentially excreted protein in diabetic nephropathy patients. Clin. Chem. 2007, 53, 1636-1645.
60. Jain, S., Rajput, A., Kumar, Y., Uppuluri, N. et al., Proteomic analysis of urinary protein markers for accurate prediction of diabetic kidney disorder. J. Assoc. Physicians India 2005, 53, 513-520.
61. Kim, H.-J., Cho, E.-J., Yoo, J.-H, Kim, P.-K. et al., Proteome analysis of serum from type 2 diabetics with nephropathy. J. Proteome Res. 2007, 6, 735-743.
62. Mischak, H., Kaiser, T., Walden, M., Hillmann, M. et al., Proteomic analysis for the assessment of diabetic renal damage in humans. Clin. Sci. (London) 2004, 107, 485-495.
63. Otu, H. H., Can, H., Spentzos, D., Nelson, R. G. et al., Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy. Diabetes Care. 2007, 30, 638-643.
64. Sharma, K., Lee, S., Han, S., Lee, S. et al., Two-dimensional fluorescence difference gel electrophoresis analysis of the urine proteome in human diabetic nephropathy. Proteomics 2005, 5, 2648-2655.
65. Xia, J. F., Liang, Q. L., Liang, X. P., Wang, Y. M., et al., Ultraviolet and tandem mass spectrometry for simultaneous quantification of 21 pivotal metabolites in plasma from patients with diabetic nephropathy. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2009, 877, 1930-1936.
66. Zhang, J., Yan, L., Chen, W., Lin, L. et al., Metabonomics research of diabetic nephropathy and type 2 diabetes mellitus based on UPLC-oaTOF-MS system. Anal. Chim. Acta. 2009, 650, 16-22.
67. Chambers, J. C., Zhang, W., Lord, G. M., van der Harst, P. et al., Genetic loci influencing kidney function and chronic kidney disease. Nat. Genet. 2010, 42, 373-375.
68. Köttgen, A., Glazer, N. L., Dehghan, A., Hwang, S. J. et al., Multiple loci associated with indices of renal function and chronic kidney disease. Nat. Genet. 2009, 41, 712-717.
69. Lim, S. C., Liu, J. J., Low, H. Q., Morgenthaler, N. G. et al., Microarray analysis of multiple candidate genes and associated plasma proteins for nephropathy secondary to type 2 diabetes among Chinese individuals. Diabetologia 2009, 52, 1343-1351.